These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8544178)

  • 1. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
    Fink CA; Qiao Y; Berry CJ; Sakane Y; Ghai RD; Trapani AJ
    J Med Chem; 1995 Dec; 38(26):5023-30. PubMed ID: 8544178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
    J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
    Olimpieri F; Tambaro S; Fustero S; Lazzari P; Sanchez-Roselló M; Pani L; Volonterio A; Zanda M
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4715-9. PubMed ID: 19596577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.
    Robl JA; Sulsky R; Sieber-McMaster E; Ryono DE; Cimarusti MP; Simpkins LM; Karanewsky DS; Chao S; Asaad MM; Seymour AA; Fox M; Smith PL; Trippodo NC
    J Med Chem; 1999 Jan; 42(2):305-11. PubMed ID: 9925736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2' position.
    Inguimbert N; Poras H; Dhotel H; Beslot F; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski MC; Roques BP
    J Pept Res; 2004 Feb; 63(2):99-107. PubMed ID: 15009531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK; Johnston CI; Burrell LM
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
    Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
    Robl JA; Cimarusti MP; Simpkins LM; Brown B; Ryono DE; Bird JE; Asaad MM; Schaeffer TR; Trippodo NC
    J Med Chem; 1996 Jan; 39(2):494-502. PubMed ID: 8558518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
    Sulpizio AC; Pullen MA; Edwards RM; Brooks DP
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1141-7. PubMed ID: 14769834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11.
    Chatelain RE; Ghai RD; Trapani AJ; Odorico LM; Dardik BN; De Lombaert S; Lappe RW; Fink CA
    J Pharmacol Exp Ther; 1998 Mar; 284(3):974-82. PubMed ID: 9495857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
    French JF; Anderson BA; Downs TR; Dage RC
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes.
    Helin K; Tikkanen I; Hohenthal U; Fyhrquist F
    Eur J Pharmacol; 1994 Oct; 264(2):135-41. PubMed ID: 7851475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel JB; Roques BP
    J Med Chem; 1994 Apr; 37(8):1070-83. PubMed ID: 8164250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
    French JF; Flynn GA; Giroux EL; Mehdi S; Anderson B; Beach DC; Koehl JR; Dage RC
    J Pharmacol Exp Ther; 1994 Jan; 268(1):180-6. PubMed ID: 8301555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.